 |
Top 37 medical and healthcare startups in Netherlands
Oct 12, 2024 | By Jason Kwon | 22 |
1
Funding: $786.3M
Founded is a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases
Founded is a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases
2
Funding: $780.7M
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. We believe our multiple partnerships and the regulatory approval of our lead product Glybera in the European Union for a subset of patients with LPLD provides validation for our approach.
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. We believe our multiple partnerships and the regulatory approval of our lead product Glybera in the European Union for a subset of patients with LPLD provides validation for our approach.
3
Funding: €160M
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
4
Funding: $149.4M
NorthSea Therapeutics is a biotech company developing first-in class, oral, structurally-engineered lipid therapeutics targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
NorthSea Therapeutics is a biotech company developing first-in class, oral, structurally-engineered lipid therapeutics targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
5
Funding: $102.9M
Lava Therapeutics has developed a proprietary platform focused on developing next generation T cell engaging bispecific antibodies.
Lava Therapeutics has developed a proprietary platform focused on developing next generation T cell engaging bispecific antibodies.
6
Funding: €96.1M
Micreos is a developer of phage technology for targeted control of bacteria. Micreos’ big idea is to use enzymes made by bacteriophages to selectively take out bacteria without drug resistance.
Micreos is a developer of phage technology for targeted control of bacteria. Micreos’ big idea is to use enzymes made by bacteriophages to selectively take out bacteria without drug resistance.
7
Funding: $64.4M
Castor offers a cloud-based clinical data platform that simplifies and streamlines clinical trials processes.
Castor offers a cloud-based clinical data platform that simplifies and streamlines clinical trials processes.
8
Funding: $54.4M
Onera advances sleep medicine by creating breakthrough diagnostic solutions that help people who struggle with sleep-related ailments.
Onera advances sleep medicine by creating breakthrough diagnostic solutions that help people who struggle with sleep-related ailments.
9
Funding: €37.6M
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.
10
Funding: €32M
Vitestro transform patient care with autonomous blood drawing technology. The company's device utilizes ultrasound-guided, AI-based 3D reconstruction with robotic needle insertion to collect a user's blood.
Vitestro transform patient care with autonomous blood drawing technology. The company's device utilizes ultrasound-guided, AI-based 3D reconstruction with robotic needle insertion to collect a user's blood.
11
Funding: $27.5M
Azafaros B.V. aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
Azafaros B.V. aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
12
Funding: €50K
Xilloc Medical aims to provide patient specific implants to reconstruct parts of the human’s skeleton.
Xilloc Medical aims to provide patient specific implants to reconstruct parts of the human’s skeleton.
13
Funding: $19M
Escalier Biosciences develops topical and oral therapeutics for treatment of psoriasis.
Escalier Biosciences develops topical and oral therapeutics for treatment of psoriasis.
14
Funding: $16.5M
SkinVision is a mobile app that allows you to understand your risk factors for skin cancer and keep track of your moles.
SkinVision is a mobile app that allows you to understand your risk factors for skin cancer and keep track of your moles.
15
Funding: $17.1M
Landcent is accelerating the fight against infectious diseases of poverty through affordable, scalable and safe technologies.
Landcent is accelerating the fight against infectious diseases of poverty through affordable, scalable and safe technologies.
16
Funding: €14M
Siilo is a secure and compliant messaging and collaboration for healthcare teams.
Siilo is a secure and compliant messaging and collaboration for healthcare teams.
17
Funding: $13.4M
An online fitness platform for consumers & professionals in the health industry
An online fitness platform for consumers & professionals in the health industry
18
LivAssured develops NightWatch - the armband that notifies caregivers remotely of nightly epileptic seizures.
19
Funding: $2M
NovioSense develops tear glucose measurement device. Their vision is to free diabetics from the painful finger prick and throughout this leverage for their shareholders the significant market potential that such a non-invasive glucose monitor could achieve.
NovioSense develops tear glucose measurement device. Their vision is to free diabetics from the painful finger prick and throughout this leverage for their shareholders the significant market potential that such a non-invasive glucose monitor could achieve.
20
Funding: €250K
ARTPred is developing technology intended to predict the odds of failure of an embryo to implant in the uterus during in-vitro fertilization procedures. The platform is based on biomarker profiles of the urogenital microbiome.
ARTPred is developing technology intended to predict the odds of failure of an embryo to implant in the uterus during in-vitro fertilization procedures. The platform is based on biomarker profiles of the urogenital microbiome.
